DK2994160T3 - Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g - Google Patents
Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g Download PDFInfo
- Publication number
- DK2994160T3 DK2994160T3 DK14730660.9T DK14730660T DK2994160T3 DK 2994160 T3 DK2994160 T3 DK 2994160T3 DK 14730660 T DK14730660 T DK 14730660T DK 2994160 T3 DK2994160 T3 DK 2994160T3
- Authority
- DK
- Denmark
- Prior art keywords
- poolet
- alzheimer
- immunoglobulin
- treatment
- subpopulations
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 229940027941 immunoglobulin g Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361855062P | 2013-05-06 | 2013-05-06 | |
| US201361833447P | 2013-06-10 | 2013-06-10 | |
| US201361844732P | 2013-07-10 | 2013-07-10 | |
| US201361886464P | 2013-10-03 | 2013-10-03 | |
| PCT/US2014/036848 WO2014182631A1 (en) | 2013-05-06 | 2014-05-05 | Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2994160T3 true DK2994160T3 (da) | 2019-08-12 |
Family
ID=50943566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14730660.9T DK2994160T3 (da) | 2013-05-06 | 2014-05-05 | Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20140328856A1 (da) |
| EP (2) | EP2994160B1 (da) |
| JP (1) | JP6424210B2 (da) |
| AU (4) | AU2014262890B2 (da) |
| DK (1) | DK2994160T3 (da) |
| ES (1) | ES2740127T3 (da) |
| HR (1) | HRP20191383T1 (da) |
| HU (1) | HUE044737T2 (da) |
| LT (1) | LT2994160T (da) |
| PL (1) | PL2994160T3 (da) |
| PT (1) | PT2994160T (da) |
| WO (1) | WO2014182631A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4289820A3 (en) | 2014-03-21 | 2024-03-13 | Alzheon, Inc. | Compounds for use in treating alzheimer's disease in apoe4+/+ patients |
| WO2016033382A1 (en) * | 2014-08-27 | 2016-03-03 | Capnia, Inc. | Methods for immune globulin administration |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| JP6789579B2 (ja) * | 2015-09-10 | 2020-11-25 | アルジオン， インコーポレイテッド | 特定の患者集団において神経変性障害を処置する方法 |
| CN114019170A (zh) * | 2016-01-20 | 2022-02-08 | 基因泰克公司 | 用于阿尔茨海默氏病的高剂量治疗 |
| HRP20211628T1 (hr) * | 2016-08-18 | 2022-02-04 | Alkahest, Inc. | Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem |
| BR112019022402A2 (pt) * | 2017-04-26 | 2020-05-19 | Alkahest Inc | regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| SI3672631T1 (sl) | 2017-08-22 | 2023-06-30 | Biogen Ma Inc. | Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu |
| FI128916B (en) * | 2018-02-05 | 2021-03-15 | Vetcare Oy | Health-promoting composition and method for its preparation |
| KR102276545B1 (ko) * | 2019-09-05 | 2021-07-15 | 고려대학교 산학협력단 | Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치 |
| NL2024431B1 (en) | 2019-12-11 | 2021-09-07 | Sulfateq Bv | Compounds for treatment of alzheimer’s disease |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
| CA3198827A1 (en) * | 2020-10-30 | 2022-05-05 | Rush University Medical Center | Intranasal immunotherapy for the treatment of alzheimer's disease |
| EP4472679A1 (en) * | 2022-02-03 | 2024-12-11 | Eli Lilly and Company | Regional tau imaging for diagnosing and treating alzheimer's disease |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (da) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| WO2003028668A2 (en) | 2001-10-04 | 2003-04-10 | Protein Therapeutics, Inc. | Gammaglobulin treatment of immune disorders |
| US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| WO2006091332A2 (en) | 2005-02-23 | 2006-08-31 | Alza Corporation | Intranasal administration of active agents to the central nervous system |
| PL1981540T3 (pl) * | 2006-01-30 | 2013-08-30 | Grifols Therapeutics Inc | Sposób leczenia i profilaktyki chorób związanych z odkładaniem się amyloidu z zastosowaniem IgM |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| TWI489994B (zh) | 2008-03-17 | 2015-07-01 | Baxter Healthcare Sa | 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法 |
| US9084743B2 (en) | 2009-09-17 | 2015-07-21 | Baxter International Inc. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| US8622993B2 (en) | 2009-12-18 | 2014-01-07 | Healthpartners Research Foundation | Device and method for delivering therapeutic substances to the maxillary sinus of a patient |
| SG184820A1 (en) * | 2010-04-13 | 2012-11-29 | Baxter Int | Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease |
| WO2011142778A1 (en) * | 2010-05-13 | 2011-11-17 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
| JP6055412B2 (ja) * | 2010-09-17 | 2016-12-27 | バクスアルタ ゲーエムベーハー | 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化 |
| KR20130139153A (ko) * | 2011-01-18 | 2013-12-20 | 백스터 인터내셔널 인코포레이티드 | 인간 혈액 중 항-베타 아밀로이드 항체의 측정 |
| US20120251524A1 (en) * | 2011-04-01 | 2012-10-04 | Baxter Healthcare S.A. | Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease |
| ES2714999T3 (es) * | 2011-09-24 | 2019-05-31 | Csl Behring Gmbh | Terapia de combinación que usa inmunoglobulina e inhibidor de C1 |
-
2014
- 2014-05-05 AU AU2014262890A patent/AU2014262890B2/en active Active
- 2014-05-05 EP EP14730660.9A patent/EP2994160B1/en active Active
- 2014-05-05 ES ES14730660T patent/ES2740127T3/es active Active
- 2014-05-05 PL PL14730660T patent/PL2994160T3/pl unknown
- 2014-05-05 WO PCT/US2014/036848 patent/WO2014182631A1/en not_active Ceased
- 2014-05-05 LT LTEP14730660.9T patent/LT2994160T/lt unknown
- 2014-05-05 HR HRP20191383TT patent/HRP20191383T1/hr unknown
- 2014-05-05 US US14/270,192 patent/US20140328856A1/en not_active Abandoned
- 2014-05-05 JP JP2016512995A patent/JP6424210B2/ja active Active
- 2014-05-05 HU HUE14730660 patent/HUE044737T2/hu unknown
- 2014-05-05 EP EP19175106.4A patent/EP3552624A1/en active Pending
- 2014-05-05 DK DK14730660.9T patent/DK2994160T3/da active
- 2014-05-05 PT PT14730660T patent/PT2994160T/pt unknown
-
2019
- 2019-01-14 US US16/247,141 patent/US20190144530A1/en not_active Abandoned
- 2019-04-09 AU AU2019202459A patent/AU2019202459B2/en active Active
-
2020
- 2020-10-19 AU AU2020257034A patent/AU2020257034A1/en not_active Abandoned
-
2021
- 2021-04-19 US US17/234,658 patent/US20210238267A1/en not_active Abandoned
-
2024
- 2024-02-19 AU AU2024201051A patent/AU2024201051A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014262890A1 (en) | 2015-11-26 |
| PL2994160T3 (pl) | 2019-10-31 |
| JP6424210B2 (ja) | 2018-11-14 |
| AU2019202459A1 (en) | 2019-05-02 |
| AU2024201051A1 (en) | 2024-03-14 |
| HRP20191383T1 (hr) | 2020-02-07 |
| ES2740127T3 (es) | 2020-02-05 |
| LT2994160T (lt) | 2019-08-26 |
| US20140328856A1 (en) | 2014-11-06 |
| US20210238267A1 (en) | 2021-08-05 |
| EP2994160B1 (en) | 2019-07-03 |
| AU2020257034A1 (en) | 2020-11-12 |
| WO2014182631A1 (en) | 2014-11-13 |
| EP3552624A1 (en) | 2019-10-16 |
| EP2994160A1 (en) | 2016-03-16 |
| AU2014262890B2 (en) | 2019-01-31 |
| JP2016518411A (ja) | 2016-06-23 |
| US20190144530A1 (en) | 2019-05-16 |
| HUE044737T2 (hu) | 2019-11-28 |
| AU2019202459B2 (en) | 2020-07-23 |
| PT2994160T (pt) | 2019-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2994160T3 (da) | Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g | |
| DK2968218T3 (da) | Kombination til behandling af parkinsons sygdom | |
| DK2955195T3 (da) | Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme | |
| HUE053239T2 (hu) | Humanizált tau-ellenanyagok Alzheimer-kór kezelésére | |
| EP2970511A4 (en) | INSULIN CONJUGATES incretin | |
| EP2932645A4 (en) | VALIDATION OF THE SAFETY OF A CENTRAL CLOUD APPLICATION | |
| DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| DK3010506T3 (da) | Pridopidin i behandling af huntingtons sygdom | |
| EP2956047A4 (en) | IRIS EXPANDER | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| EP3065624A4 (en) | AUTOMATED DETECTION OF EYE ALIGNMENT | |
| EP2964658A4 (en) | SUBSTITUTED ORGANOFLUORBORATES AS IMAGING AGENTS | |
| EP2983654A4 (en) | Treatment of cancer using coenzyme q10 combination therapies | |
| EP2868258A4 (en) | IMAGING SYSTEM | |
| DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
| EP3379317A4 (en) | IMAGING LENS | |
| EP2997047A4 (en) | heparansulphates | |
| EP3291722A4 (en) | IMPROVED LENS OPPORTER | |
| EP2959219A4 (en) | Class 1 compliant lens assembly | |
| DK2961426T3 (da) | Behandling af sygdomme i centralnervesystemet ved intranasal indgivelse af immunoglobulin g | |
| HUE059507T2 (hu) | BAFF-ra és B7RP1-re specifikus fehérjék és alkalmazásuk | |
| DK3041831T3 (da) | Alfa-te-saltformer: sammensætninger og anvendelser til behandling af sygdom | |
| DK2964185T3 (da) | Præparater til behandlingen af søvnrelaterede luftvejslidelser | |
| DK3024816T3 (da) | Ppar-sparende forbindelser til behandling af metaboliske sygdomme |